By Xzencis AB
To get in touch with Xzencis AB, simply fill out the form below.
Subscribe to Supplier
Xzencis partners with ApconiX to bring Translational Safety insights to ICT Maastricht
Mölnlycke, Sweden: – Expert pharma and life sciences safety consultant Xzencis will contribute its founder and Managing Director Dr. Steffen Ernst as a prominent translational safety expert at the upcoming 16th– XVIth International Congress of Toxicology (ICT2022) in Maastricht.
Dr. Ernst will join long term collaborators Dr. Richard Knight and Prof. Ruth Roberts of UK-based ApconiX Ltd on their stand at Booth 63 in the Exhibition Zone at the MECC exhibition centre in Maastricht.
New safety approaches
ApconiX was founded in 2015 as an integrated toxicology and ion channel company providing new approaches to world-class nonclinical safety expertise for biotech, biopharma and academia.
Dr. Ernst’s presence on the ApconiX stand provides ICT toxicology professionals to hear his insights as a consulting expert on a radically new approach to drug and patient safety that goes beyond the limitations of traditional pharmacovigilance (PV).
Translational Safety Medicine
Dr. Ernst and Dr. Knight were co-authors of key chapters on toxicology that form part of the most comprehensive book on Translational Medicine, Principles of Translational Science in Medicine: From Bench to Bedside, edited by Prof. Dr. Martin Wehling, of the University of Heidelberg’s Clinical Pharmacology Department in Mannheim.
This is part of a vision of a more proactive and forward-looking approach to safety management, as well as stressing transational safety as a discipline covering the whole product life cycle and all parts of the organisation that Dr. Ernst will share with ICT visitors and delegates as part of the ApconiX team.
About Xzencis AB
Xzencis provides a wide suite of expert consultancy services focused on Translational Safety Solutions: planning and executing transitions and problem solving along the entire pharmaceutical value chain from pre-clinical target to market launch and beyond.
The company’s strength is based on in-depth subject matter expertise in medicinal regulation, toxicology, clinical Patient Safety (PS) and Pharmacovigilance (PV), business administration, business development and licensing uniquely combined with hands-on business experience. These allow us to assist any life sciences company or organization with safety and regulatory issues, such as strategy development and execution, pre-clinical and clinical challenges, inbound or outbound licensing, building safety value chains, governance, Due Diligence assessments for investors and organizational design of safety departments.
Where extra personnel are required, Xzencis can call on an extensive network of senior, experienced Toxicologists, NCDS sub-discipline experts, Safety Physicians, Safety Scientists and PV Systems experts – all with tested and proven, impeccable track records.
Learn more at: www.xzencis.com
First staged in 2004, the provides an annual expert knowledge-sharing forum for toxicological scientists worldwide.
Reconvening after a two year break under the banner theme ‘Uniting in Toxicology’, the 16th International Congress of Toxicology (ICT2022) will be a four-day event opening September 18, 2022, at the Maastricht Exposition and Conference Centre (MECC) in the Netherlands.
The congress scientific program features keynote lectures, debates, smaller symposia and workshops, along with a co-located exhibition. It pays special attention to early career toxicologist with a dedicated platform for oral communications.
The event is jointly organized by the International Union of Toxicology (IUTOX) and the European Society of Toxicology (EUROTOX), with further information at: www.ict2022.com